Investigational combination therapy CagriSema demonstrated significant weight reduction and noninferior HbA1c lowering in phase 3 clinical trials.

Probiotic supplement use has surged in the United States, while the consumption of microbiome-supportive foods has remained unchanged, according to a study publ ...

Trimodal therapy can be an alternative to radical cystectomy for select patients with cT2-4aN0M0 muscle-invasive bladder cancer.

HealthDay News — High-frequency spinal cord stimulation significantly reduces pain and improves sensory function in people with painful diabetic neuropathy, according to a study published online ...

HealthDay News — For adults with type 2 diabetes receiving sodium-glucose cotransporter-2 (SGLT2) inhibitors, risk factors for ketoacidosis include high hemoglobin A1c, previous ketoacidosis, and ...

Approval of the nonsteroidal mineralocorticoid receptor antagonist provides the first new treatment option in over 30 years for kidney disease in adults with type 1 diabetes.

Results from the final ORIGIN 3 analysis reveal that atacicept over 104 weeks significantly reduced the risk of a composite kidney disease progression event by 76% in adults with primary IgA ...

Phase 3 CELESTIMO study demonstrates significant progression free survival benefit for an mosunetuzumab combination regimen ...

Phase 3 COVER DFUS II trial data show the autologous therapy plus standard of care significantly improves wound closure rates at 12 weeks.

Biweekly enzyme replacement therapy demonstrates efficacy in pediatric and adult hypophosphatasia while offering lower injection frequency.

Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib ...